EPO and chronic kidney disease: Some researchers have pointed to increased levels of inflammatory cytokines, such as interferon and tumor necrosis factor-alpha (TNF-α), commonly observed in CKD, which may lead to a decreased sensitivity of erythroid progenitors to EPO [22,23].